Martin J. Driscoll

Chief Executive Officer

Mr. Driscoll, appointed chief executive officer (CEO) of Asmacure on April 13, 2011, brings more than 30 years of pharmaceutical industry experience to the company.  His experience includes senior roles in general management, commercial operations and business development for both privately-held and publicly-traded life sciences commercial- and development-stage companies. Mr. Driscoll also has served as a director on the boards of three private and public biopharmaceutical development companies..

Previously, Mr. Driscoll was the CEO and a director of Javelin Pharmaceuticals, Inc., a developer of acute care pain products, from March 2008 until July 2010 when he engineered the successful merger of Javelin with Hospira, Inc.  During his career, Mr. Driscoll has worked at Schering-Plough, ViroPharma, Inc and Reliant Pharmaceuticals. During his career at Schering-Plough, Mr. Driscoll was the general manager of Key Pharmaceuticals, the Schering-Plough Unit responsible for all respiratory products in the U.S.  In 2007, Mr. Driscoll co-founded Pear Tree Pharmaceuticals, a privately-held developer of women’s healthcare products. Mr. Driscoll has been involved with or led the commercialization of four blockbuster therapies, the direct negotiation of multiple transactions, licensing and M&A, and the successful submission of multiple major product regulatory filings.

Mr. Driscoll holds a B.Sc. in communications from the University of Texas at Austin. He is a board member of the Barn for the Poorest of the Poor, a local food pantry based in New Jersey..


Dr Yvon Cormier, MD, C.S.P.Q., F.R.C.P. (c)

Founder and Chief Medical Officer

Dr. Cormier founded Asmacure in 2002 with Evelyne Israel-Assayag and is the chief medical officer. He was director of the Quebec “Réseau en Santé Respiratoire” of the FRSQ from 1999 to 2005 and director of the IUCPQ research center from 1990 to 1999. He was associate dean of research and graduate studies of Laval University’s faculty of medicine from 2000-2010. He has held the position of pulmonary clinical research at the IUCPQ since 1977. He was appointed Assistant Professor of medicine at the department of Medicine, Faculty of Medicine, Laval University in 1981 and made a full Professor in 1991. He has authored or co-authored 237 peer review scientific papers, contributed 27 book chapters, most of which in internationally recognized manuals ( examples: l’Encyclopedie Médico Chirurgicale, Elsevier Paris; Textbook of Pulmonary Medicine, Mosby-Year Book; Asthma in the Workplace, Marcel Dekker;). He co-edited the textbook “Pneumologie Clinique” Press de Université de Montréal. He is associate editor of the Canadian Respiratory Journal and of the Annals of Agricultural and Environmental Medicine. He served as president of the Canadian Thoracic society and as a member of the board of the American Thoracic Society.

After completing his bachelor’s degree at l’Université de Moncton, N.B, he received his medical degree from Laval University, Quebec City and did his clinical training at Laval Hospital, now l’Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ). Dr. Cormier did a research fellowship at the Johns’ Hopkins Hospital, Baltimore., Md.


Lise Breton, CA

Vice President, Finance and Administration

Ms. Breton has been the vice president of finance and administration at Asmacure since February 2007. She supports Asmacure’s financing activities, as well as the company’s overall operations and budget management and planning. She has over 23 years experience in R & D management.

She has been tasked with managing all financial, accounting, and human and material resources operations of a variety of businesses. She has been involved in various transactions of mergers and acquisitions in the biopharmaceutical field. She currently serves on the board and as the Chairman of the Audit Committee of La Société des Traversiers du Québec, a governmental organization. She also acts as Corporate Secretary. She earned a degree in law and accounting from Université Laval.


Evelyne Israel-Assayag, M.Sc.

Co-Founder and Vice President, Pre-Clinical Research and Development

Ms. Assayag is the co-founder of Asmacure and serves as the vice president of pre-clinical research and development. She oversees Asmacure internal and external research activities, including the studies pertaining to the preclinical inflammation and/or asthma models. Ms Assayag is also involved in preclinical and clinical pharmacokinetics, chemistry, manufacturing and formulation, and is responsible for the planning, design and supervision of the external nonclinical safety GLP programs.

Ms. Assayag has over 25 years of experience in basic and medical research in inflammatory lung diseases, 20 of which as Dr. Cormier’s collaborator. She is author or co-author of over 65 scientific publications and book chapters and 85 communications in basic research. She received her bachelor’s degree and master’s degree in microbiology and immunology from Hebrew University of Jerusalem.


Marie-Claude Pepin, Ph.D.

Vice President, Corporate Affairs and Planning

Dr. Pepin joined Asmacure in 2007 and is supporting Asmacure’s intellectual property activities, non-dilutive financing activities as well as the company’s Business and Scientific watch. She has over 19 years of experience in the pharmaceutical and biotechnologicalindustries.

Prior to joining Asmacure, she was vice president of Life Sciences at Inno-Centre, a company specializing in business coaching of high-tech start-up companies. In addition, Dr. Pepin was director of QC and R&D Laboratories at AeternaZentaris, assistant director of molecular biology department at AstraZeneca and research associate at the Biotechnology Research Institute (National Research Council of Canada).

She received her bachelor’s degree, a Ph.D. Degree in Cellular and Molecular Biology and a Certificate in Business Valuation from Université Laval.